source
- Rocket Pharmaceuticals aligns with FDA on Danon therapy as Novo exits Ascendis and Lilly announces new dealRocket Pharmaceuticals said it has reached alignment with the U.S. FDA regarding its commercial-stage program for Danon disease, indicating the agency and the company are on the same page about the…
- Omada Health posts first profitable quarter and prepares CEO successionOmada Health, a digital health company, completed its IPO a little over a year ago and has now posted its first profitable quarter, achieved in the spring. The profitability marks a milestone for…